Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Durable Remissions with the VcR-CVAD Regimen for Mantle Cell Lymphoma (MCL), Regardless of Age: Long-Term Follow-up of a Wisconsin Oncology Network (WON) Study

Julie E. Chang, MD, Christopher Peterson, MD, Lakeesha L. Carmichael, MS, KyungMann Kim, PhD, David T. Yang, MD, Anne M. Traynor, MD, Jae E. Werndli, BSc, MSc, Michael Huie, MD, Thomas McFarland, MD, Michael Volk, MD, Jules H. Blank, MD, Natalie S. Callander, MD, Walter L. Longo, MD, Brad S. Kahl, MD

Blood (2016) 128 (22): 149.

https://doi.org/10.1182/blood.V128.22.149.149

Published: 2016

Journal Articles

Angiogenic Blockade with Bevacizumab Does Not Increase Response to Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Myeloma

Andrew T Humbert, Rachel Cook, MS, MD, Thomas McFarland, Ronald Go, MD, Stephanie Markovina, MD, Shigeki Miyamoto, PhD, Eliot C. Williams, MD, PhD, Fotios Asimakopoulos, MBBChir, PhD, Jill Kolesar, PhD, Michael A. Thompson, MD, PhD, Kyungmann Kim, Natalie Callander, MD

Blood (2012) 120 (21): 5041.

https://doi.org/10.1182/blood.V120.21.5041.5041

Published: 2012

Journal Articles

VcR-CVAD Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma: A Phase II Study from the Wisconsin Oncology Network

Brad Kahl, Julie Chang, Jens Eickhoff, Leslie Gilbert, Eric Rogers, Jae Werndli, Michael Huie, Thomas McFarland, Michael Volk, Jules H. Blank, Natalie Callander, Walter Longo, Christopher Peterson

Blood (2008) 112 (11): 265.

https://doi.org/10.1182/blood.V112.11.265.265

Published: 2008

Journal Articles

Phase II Trial of Bevacizumab Combined with Low Dose Dexamethasone and Lenalidomide (BEV/REV/DEX) for Relapsed or Refractory Myeloma (MM).

Martha Raschko, MD, Stephanie Markovina, Shigeki Miyamoto, PhD, Walter Longo, MD, Eliot Williams, MD, Thomas McFarland, MD, Jae Werndli, Elisabeth Wagner, Mark Juckett, MD, Natalie Callander, MD

Blood (2007) 110 (11): 1173.

https://doi.org/10.1182/blood.V110.11.1173.1173

Published: 2007

Journal Articles

Phase II Study of Modified Hyper-CVAD with Rituximab Maintenance for Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.

Brad S. Kahl, MD, James McGovern, MD, Jules Blank, MD, Anthony Jaslowski, MD, Gerald Bayer, MD, Wayne A. Bottner, MD, Hamied Rezazadeh, MD, Thomas McFarland, MD, David Hei, MD, Jamie Smith, Emily A. Stevens, Jens C. Eickhoff, Ph.D., Walter L. Longo, MD

Blood (2004) 104 (11): 1388.

https://doi.org/10.1182/blood.V104.11.1388.1388

Published: 2004

NARROW

Durable Remissions with the VcR-CVAD Regimen for Mantle Cell Lymphoma (MCL), Regardless of Age: Long-Term Follow-up of a Wisconsin Oncology Network (WON) Study

Angiogenic Blockade with Bevacizumab Does Not Increase Response to Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Myeloma

VcR-CVAD Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma: A Phase II Study from the Wisconsin Oncology Network

Phase II Trial of Bevacizumab Combined with Low Dose Dexamethasone and Lenalidomide (BEV/REV/DEX) for Relapsed or Refractory Myeloma (MM).

Phase II Study of Modified Hyper-CVAD with Rituximab Maintenance for Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.

Email alerts

ASH Publications

American Society of Hematology

Durable Remissions with the VcR-CVAD Regimen for Mantle Cell Lymphoma (MCL), Regardless of Age: Long-Term Follow-up of a Wisconsin Oncology Network (WON) Study

Angiogenic Blockade with Bevacizumab Does Not Increase Response to Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Myeloma

VcR-CVAD Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma: A Phase II Study from the Wisconsin Oncology Network

Phase II Trial of Bevacizumab Combined with Low Dose Dexamethasone and Lenalidomide (BEV/REV/DEX) for Relapsed or Refractory Myeloma (MM).

Phase II Study of Modified Hyper-CVAD with Rituximab Maintenance for Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only